To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Gilead, Ipsen, Depomed

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at Novartis AG

Read the full 374 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE